Michael Jirousek - Catabasis Pharmaceuticals Insider

CATB -- USA Stock  

USD 0.83  0.01399  1.66%

  Founder
Dr. Michael Jirousek, Ph.D. is the CoFounder and Chief Scientific Officer of Catabasis Pharmaceuticals, Inc. He has more than twenty years of experience in pharmaceutical research and development. Prior to joining the Company, he was a Corporationrationrate Officer and Senior Vice President of research at Sirtris Pharmaceuticals, where he was Head of Research for the company. He joined Sirtris from Pfizer La Jolla, part of Pfizer Global Research and Development, where he was Senior Director and Head of the Metabolic Therapeutic Area. He founded the La Jolla group. Prior to joining Pfizer, he was the Department Head at Abbott Laboratories for three years. He spent eight years at Eli Lilly in Indianapolis and Hamburg, Germany, focusing on diabetic complications and PKC inhibitors
Age: 55  Founder Since 2008  Ph.D    
617-349-1971  http://www.catabasis.com
Jirousek holds a Ph.D. in chemistry from Case Western Reserve University and was a postdoctoral fellow at Harvard University and holds a Ph.D. in Chemistry from Case Western University and a B.S. in Chemistry from Kent State University.

Management Efficiency

The company has return on total asset (ROA) of (39.47) % which means that it has lost $39.47 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (79.11) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 831 K in liabilities with Debt to Equity (D/E) ratio of 1.8 which is about average as compared to similar companies. Catabasis Pharmaceuticals has Current Ratio of 10.02 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts. Catabasis Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 36 people.Catabasis Pharmaceuticals (CATB) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 36 people. Catabasis Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Catabasis Pharmaceuticals Leadership Team

Jean George, Director
Angelika Fretzen, Senior Vice President - Product Development
Rick Modi, Chief Business Officer
Joanne Donovan, Chief Medical Officer
Deirdre Cunnane, Senior Vice President General Counsel
Michael Jirousek, Co-Founder and Member of Scientific Advisory Board
Michael Kishbauch, Director
Edward Hibben, Chief Business Officer
Ian Sanderson, CFO, Treasurer
Burt Adelman, Director
Deirdre JD, Sr. VP and General Counsel
Kenneth Bate, Director
Jill Milne, Co-Founder, CEO and President and Director
Andrea Matthews, IR Contact Officer
Nicholas Galakatos, Director
Ron Laufer, Director
Michael Ross, Chairman of the Board
Andrew Nichols, Sr. VP of Research
Ted Hibben, Sr. VP of Corporate Devel.

Stock Performance Indicators

Current Sentiment - CATB

Catabasis Pharmaceuticals Investor Sentiment

Most of Macroaxis users are currently bullish on Catabasis Pharmaceuticals. What is your opinion about investing in Catabasis Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Catabasis Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Catabasis Pharmaceuticals and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.
Search macroaxis.com